Pulmatrix (PULM) Receivables - Other (2019 - 2020)
Pulmatrix (PULM) posted Receivables - Other of $45.0 million for Q4 2020, up 221.43% sequentially from $14.0 million in Q4 2019, and up 221.43% YoY from $14.0 million in Q1 2020.
Pulmatrix (PULM) Receivables - Other (2019 - 2020) Analysis & Trends
Pulmatrix has reported Receivables - Other for 2 years, with the latest figure at $45.0 million in Q4 2020.
- Quarterly Receivables - Other rose 221.43% year-over-year to $45.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $45.0 million (up 221.43% YoY) and the FY2020 annual result came in at $45.0 million, up 221.43% from the prior year.
- Receivables - Other improved to $45.0 million in Q4 2020 per PULM's latest filing, from $14.0 million in the prior quarter.
- Over five years, Receivables - Other peaked at $45.0 million in Q4 2020 and troughed at $14.0 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Pulmatrix | 5.62 Mn | 5.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 45.00 Mn |
| Dec 31, 2020 | 45.00 Mn |
| Dec 31, 2019 | 14.00 Mn |
| Dec 31, 2019 | 14.00 Mn |